Teva's Opioid Order Monitoring On Hot Seat In NY Trial

By Cara Salvatore (August 2, 2021, 9:46 PM EDT) -- A New York jury heard Monday of serious issues with drugmaker Teva's opioid sales safeguards, including a situation in which customer service unilaterally overrode a hold on a potentially suspicious order.

The jury hearing opioid-crisis claims in the Empire State watched two depositions Monday detailing procedures and events within Teva: one from then-manager of suspicious order monitoring Joe Tomkiewicz, and a second from Tomkiewicz's onetime boss, former director of Drug Enforcement Administration compliance Colleen McGinn, both taken in late 2018 to discuss how suspicious orders were found and treated within the company.

An instant messaging conversation between the two revealed some of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!